Literature DB >> 20205512

Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation.

Kaoru Tamura1, Masaru Aoyagi, Hiroaki Wakimoto, Noboru Ando, Tadashi Nariai, Masaaki Yamamoto, Kikuo Ohno.   

Abstract

OBJECT: Recent evidence suggests that a glioma stem cell subpopulation might contribute to radioresistance in malignant gliomas. To investigate this hypothesis, the authors examined recurrent malignant gliomas for histopathological changes after high-dose irradiation with Gamma Knife surgery (GKS) and external beam radiation therapy (EBRT).
METHODS: Thirty-two patients with malignant gliomas (Grade 3 in 8 patients, Grade 4 in 24) underwent GKS in combination with EBRT. Serial MR and L-[methyl-(11)C] methionine PET images were employed to assess remnant or recurrent tumors after GKS. Twelve patients underwent surgical removal after GKS and EBRT. Histological sections were subjected to immunohistochemistry for MIB-1, factor VIII, and stem cell markers, nestin and CD133.
RESULTS: The site of GKS treatment failure was local in 16 (76.2%) of 21 patients with glioblastomas showing progression; in 9 of these 16 patients, the recurrence clearly arose within the target lesion of GKS. Histopathological examination after GKS and EBRT showed variable mixtures of viable tumor tissues and necrosis. Viable tumor tissues exhibited high MIB-1 indices but reduced numbers of tumor blood vessels. There was marked accumulation of CD133-positive glioma cells, particularly in remnant tumors within the necrotic areas, in sections obtained after GKS plus EBRT, whereas CD133-positive cells appeared very infrequently in primary sections prior to adjuvant treatment.
CONCLUSIONS: The results indicate that CD133-positive glioma stemlike cells can survive high-dose irradiation, leading to recurrence, despite prolonged damage to tumor blood vessels. This could be an essential factor limiting the effectiveness of GKS plus EBRT for malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20205512     DOI: 10.3171/2010.2.JNS091607

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  48 in total

1.  The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.

Authors:  Muhammad Jamal; Barbara H Rath; Patricia S Tsang; Kevin Camphausen; Philip J Tofilon
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

Review 2.  Overcoming therapeutic resistance in glioblastoma: the way forward.

Authors:  Satoru Osuka; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

3.  Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.

Authors:  M Venere; P Hamerlik; Q Wu; R D Rasmussen; L A Song; A Vasanji; N Tenley; W A Flavahan; A B Hjelmeland; J Bartek; J N Rich
Journal:  Cell Death Differ       Date:  2013-10-11       Impact factor: 15.828

Review 4.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

5.  Cancer stem cells in glioma: challenges and opportunities.

Authors:  Jialiang Wang; Yufang Ma; Michael K Cooper
Journal:  Transl Cancer Res       Date:  2013-10-01       Impact factor: 1.241

6.  MiR-29a-Mediated CD133 Expression Contributes to Cisplatin Resistance in CD133+ Glioblastoma Stem Cells.

Authors:  Liang Yang; Nan Li; Zhongjie Yan; Chen Li; Zongmao Zhao
Journal:  J Mol Neurosci       Date:  2018-09-29       Impact factor: 3.444

7.  LAPTM4B-35 is a novel prognostic factor for glioblastoma.

Authors:  Xiaoshud Dong; Kaoru Tamura; Daisuke Kobayashi; Noboru Ando; Kazutaka Sumita; Taketoshi Maehara
Journal:  J Neurooncol       Date:  2017-01-18       Impact factor: 4.130

Review 8.  p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.

Authors:  Christie Rodriguez-Ramirez; Jacques E Nör
Journal:  Crit Rev Oncog       Date:  2018

9.  Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.

Authors:  Joshua C Anderson; Christine W Duarte; Karim Welaya; Timothy D Rohrbach; Markus Bredel; Eddy S Yang; Nirmal V Choradia; Jaideep V Thottassery; George Yancey Gillespie; James A Bonner; Christopher D Willey
Journal:  Radiother Oncol       Date:  2014-05-08       Impact factor: 6.280

10.  Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.

Authors:  Robin G Lerner; Stefan Grossauer; Banafsheh Kadkhodaei; Ian Meyers; Maxim Sidorov; Katharina Koeck; Rintaro Hashizume; Tomoko Ozawa; Joanna J Phillips; Mitchel S Berger; Theodore Nicolaides; C David James; Claudia K Petritsch
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.